Fully human egfr ScFv tobacco codon-biased gene sequence and its obtaining method and application

Abstract

The invention discloses a human EGFR ScFv tobacco codon preference gene sequence as well as an acquiring method and an application thereof. The acquiring method of the gene sequence comprises the following steps: acquiring a human EGFR ScFv gene sequence, changing the human EGFR ScFv gene sequence, additionally arranging an enzyme cutting point Xba1 and BamH1 to the changed VH-L-VL gene sequence, arranging a protective basic group, and placing a histidine tag behind ATG, placing three end codons in the enzyme cutting point of the end 5minute. By adopting the human EGFR ScFv tobacco codon preference gene sequence, the human anti-mouse antibody reaction of mouse-sourced gene sequence in the human body and other adverse reactions caused by other sourced gene sequences can be avoided. The human EGFR ScFv effectively expressed by utilizing a plant biological reactor of the tobacco has an antitumor effect.

Description

technical field [0001] The invention belongs to the field of using a plant bioreactor to produce an antitumor drug, in particular to a fully human EGFR ScFv tobacco codon preference gene sequence and its obtaining method and application. Background technique [0002] At present, the use of chemotherapy to treat cancer has become a routine treatment method, but chemotherapy has its application bottleneck. Now there is an urgent need for another medical method to break through the bottleneck of chemotherapy. Cancer biotherapy has become the fourth method after the three classic tumor treatment methods of surgery, chemotherapy and radiotherapy. Epidermal growth factor receptor (EGFR) is a multifunctional glycoprotein widely distributed on cell membranes of various tissues in the human body. Abnormal expression of EGFR can lead to continuous activation of cell signaling pathways and eventually lead to tumorigenesis (non-patent literature 1). EGFR is a tyrosine protein kinase r...

AI Technical Summary

Problems solved by technology

However, since most of the monoclonal antibodies prepared at present are of mouse origin, it is easy to produce human anti-mouse antibody reaction in vivo, and their large molecular weight and poor vascular permeability have brought certain difficulties to clinical application.

However, there have been no reports on the construction and application of fully human anti-EGFR ScFv

Images